Resources
25 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
It’s All About That Data (Panel Discussion) Webinar Reccording
Posted 12/11/2019 (updated 3/28/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the Implementation and NAS grantees. These measures are pending OMB clearance and are subject to revision.
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed considerations in engaging and treating individuals with stimulant use disorders and presented evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 2/24/2021 (updated 4/4/2024)
This webinar provided new information on the risks and clinical challenges presented by individuals who use psychostimulants (cocaine, methamphetamine and prescription stimulants). A review of the clinical strategies that are important in working with this population were presented, including psychosocial and medication treatments for those with stimulant use disorder. Presented by Richard Rawson, Ph.D.
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 9/1/2021 (updated 4/2/2024)
Deliverable Guidance: PIMS
Kathleen Meyers, PhD, and Rebecca Schachtner, PhD, JBS International
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 11/11/2021 (updated 4/3/2024)
Performance Improvement Measurement System